Olympus Optical Co. will begin supplying genetic medical support systems and related services in April in the hope of generating 30 billion yen in sales in the new field in 2005, it announced Tuesday.

Olympus will initially focus on services and equipment for research into genetic drug discoveries and cancer treatments using genome-related technologies. Around 2003, it will enter the market for genetic clinical applications.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.